Trinity Biotech (NASDAQ:TRIB) Receives New Coverage from Analysts at assumed coverage on shares of Trinity Biotech (NASDAQ:TRIBGet Free Report) in a research report issued to clients and investors on Monday. The firm set a “buy” rating on the stock.

Trinity Biotech Stock Down 0.6 %

Trinity Biotech stock opened at $1.65 on Monday. The company has a market cap of $12.57 million, a price-to-earnings ratio of -0.59 and a beta of 1.24. The firm’s fifty day moving average is $1.79 and its 200 day moving average is $2.13. Trinity Biotech has a 52-week low of $1.49 and a 52-week high of $5.50.

Trinity Biotech (NASDAQ:TRIBGet Free Report) last released its quarterly earnings results on Thursday, April 4th. The company reported ($0.68) earnings per share (EPS) for the quarter. The company had revenue of $13.43 million for the quarter. On average, equities research analysts anticipate that Trinity Biotech will post -2.17 earnings per share for the current fiscal year.

Trinity Biotech Company Profile

(Get Free Report)

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Featured Articles

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with's FREE daily email newsletter.